+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A Descriptive analysis of a Real-World Population with Chronic Hepatitis C (CHC) treated with Simeprevir (SMV)- and/or Sofosbuvir (SOF)-based regimens: findings from a us payer database

A Descriptive analysis of a Real-World Population with Chronic Hepatitis C (CHC) treated with Simeprevir (SMV)- and/or Sofosbuvir (SOF)-based regimens: findings from a us payer database

Value in Health 18(3): A227-A228

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 064611969

Download citation: RISBibTeXText

DOI: 10.1016/j.jval.2015.03.1321

Related references

Final Evaluation of 955 Hcv Patients Treated With 12 Week Regimens Containing Sofosbuvir +/- Simeprevir in the Trio Network: Academic and Community Treatment of a Real-World, Heterogeneous Population. Gastroenterology 148(4): S-1001, 2015

Sofosbuvir-Containing Regimens for Chronic Hepatitis C Are Successful in the Safety-Net Population: A Real-World Experience. Digestive Diseases and Sciences 61(12): 3602-3608, 2016

The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir. Clinicoeconomics and Outcomes Research 7: 637-642, 2016

Effectiveness of sofosbuvir and ledipasvir/sofosbuvir based regimens in hepatitis C virus genotype 3 infection: real-world data from Georgian hepatitis C elimination program. Journal of Hepatology 68: S281-S282, 2018

Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: Results from the multicenter German hepatitis C cohort (GECCO-03). Journal of Medical Virology 90(2): 304-312, 2017

Efficacy and safety of sofosbuvir plus simeprevir therapy in Egyptian patients with chronic hepatitis C: a real-world experience. Gut 66(11): 2008-2012, 2016

Real-World Single-Center Experience with Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C Genotype 1 Patients. Gut and Liver 11(5): 711-720, 2017

Cost-effectiveness analysis of sofosbuvir-simeprevir regimens for chronic hepatitis C genotype 1 patients with advanced fibrosis. Medicina Clinica 146(2): 61-64, 2017

Tu1014 Single-Center Real-World Experience of Sofosbuvir Plus Simeprevir for 12 Weeks for Genotype 1 Chronic Hepatitis C With Advanced Fibrosis. Gastroenterology 148(4): S-1084, 2015

Real-world Experience with Sofosbuvir-based Regimens for Chronic Hepatitis C, Including Patients with Factors Previously Associated with Inferior Treatment Response. Hawai'i Journal of Medicine and Public Health 74(9 Suppl 2): 3-7, 2016

Real-World Effectiveness of Simeprevir-containing Regimens Among Patients With Chronic Hepatitis C Virus: The SONET Study. Open Forum Infectious Diseases 4(1): Ofw258, 2017

Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium. Plos One 12(1): E0170933, 2017

Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results. World Journal of Virology 6(4): 59-72, 2017

Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotypes 1-4 and 6 in Myanmar: Real-world experience. Journal of Viral Hepatitis 24(11): 927-935, 2017

Simeprevir and Sofosbuvir with or without Ribavirin in Genotype 1 Chronic Hepatitis C Patients: Efficacy and Safety in Real Life. Journal of Hepatology 64(2): S765-S766, 2016